Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
On 30 April 2026, Axsome Therapeutics announced the FDA approval of Auvelity (dextromethorphan + bupropion) for the treatment of agitation…
Analyst Comment
Low patient accrual continues to hinder male infertility trials
Meta-analysis backs broader use of BP therapy in CKD
Study finds dose-response relationship between gestational age and autism risk
Malaria vector Anopheles (Nyssorhynchus) darlingi evolving insecticide resistance
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
